Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma

  • Authors:
    • Ayodele A. Alaiya
    • Mai Al-Mohanna
    • Muhammad Aslam
    • Zakia Shinwari
    • Layla Al-Mansouri
    • Maha Al-Rodayan
    • Maha Al-Eid
    • Irfan Ahmad
    • Kamal Hanash
    • Asma Tulbah
    • Ali Bin Mahfooz
    • Chaker Adra
  • View Affiliations

  • Published online on: February 8, 2011     https://doi.org/10.3892/ijo.2011.937
  • Pages: 1047-1057
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prostate adenocarcinoma often presents at a late stage, due to a lack of early clinical symptoms and lack of accurate objective markers. This study aimed to identify and validate proteomics-based biomarkers useful for prostate cancer diagnosis and to establish a marker-panel for prostate cancer and benign prostate hyperplasia (BPH). Global protein expression patterns in fresh tissue specimens from 8 patients with prostate carcinoma and 16 with BPH were analyzed by two-dimensional gel electrophoresis. Differentially expressed proteins were identified by MALDI-TOF mass spectrometry. We compared our results with those of published studies and defined a set of common biomarkers. We identified 22 differentially expressed proteins between BPH and prostate carcinomas. The up-regulated proteins in cancer compared to BPH included protein disulfide-isomerase, 14-3-3-protein, Enoyl CoA-hydrase, prohibitin and B-tubulin β-2. Keratin-II, desmin, HSP71, ATP-synthase-β-chain and creatine kinase-β-chain were down-regulated. Survey of the literature showed that 15 of our 22 identified proteins have been previously reported to differ in their expression levels between BPH and prostate cancer by other laboratories. The expression patterns of these biomarkers could successfully cluster BPH and adenocarcinomas as well as prostate cancer of low and high Gleason scores. This study validates protein-biomarkers that can be useful for accurate diagnosis and prognostic monitoring of prostate adenocarcinoma. Despite varied prevalence of the disease between different ethnic populations (i.e., high in Sweden, low in Saudi Arabia); the biomarkers indicate that BPH and prostate cancers are biologically ‘homogeneous’ in their protein expression patterns across wide geographical regions.

Related Articles

Journal Cover

April 2011
Volume 38 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Alaiya AA, Al-Mohanna M, Aslam M, Shinwari Z, Al-Mansouri L, Al-Rodayan M, Al-Eid M, Ahmad I, Hanash K, Tulbah A, Tulbah A, et al: Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma . Int J Oncol 38: 1047-1057, 2011
APA
Alaiya, A.A., Al-Mohanna, M., Aslam, M., Shinwari, Z., Al-Mansouri, L., Al-Rodayan, M. ... Adra, C. (2011). Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma . International Journal of Oncology, 38, 1047-1057. https://doi.org/10.3892/ijo.2011.937
MLA
Alaiya, A. A., Al-Mohanna, M., Aslam, M., Shinwari, Z., Al-Mansouri, L., Al-Rodayan, M., Al-Eid, M., Ahmad, I., Hanash, K., Tulbah, A., Mahfooz, A. B., Adra, C."Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma ". International Journal of Oncology 38.4 (2011): 1047-1057.
Chicago
Alaiya, A. A., Al-Mohanna, M., Aslam, M., Shinwari, Z., Al-Mansouri, L., Al-Rodayan, M., Al-Eid, M., Ahmad, I., Hanash, K., Tulbah, A., Mahfooz, A. B., Adra, C."Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma ". International Journal of Oncology 38, no. 4 (2011): 1047-1057. https://doi.org/10.3892/ijo.2011.937